Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03634800 · ClinicalTrials.gov registry record · Phase 2
Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03634800 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 6 participants.
The verdict
NCT03634800, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Eligible patients have multiple myeloma with measurable disease in the blood and a targetable soft tissue or bony lesion with radiotherapy. All eligible patients will receive immunotherapy (Nivolumab) plus radiotherapy, 6 Gy x 5 fractions, to a targetable lesion. Immunotherapy treatment starts with the first radiotherapy fraction. Nivolumab will be given every 2 weeks. Patients will have specified laboratory values measured bi-monthly and evaluated for response at 12 weeks as defined by International Myeloma Working Group Criteria. Patients will continue to receive their respective immunotherapy until disease progression or dose limiting toxicity is reached.
Interventions
- RADIATION Radiation therapy
- DRUG Nivolumab 240mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2020-01-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03634800
The ClinicalTrials.gov registry entry for NCT03634800 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiation therapy is the first listed.
NCT03634800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03634800 about?
NCT03634800 is a clinical study titled "Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)". Eligible patients have multiple myeloma with measurable disease in the blood and a targetable soft tissue or bony lesion with radiotherapy. All eligible patients will receive immunotherapy (Nivolumab) plus radiotherapy, 6 Gy x 5 fractions, to a targetable lesion. Immunotherapy treatment starts with ...
What is the current status of trial NCT03634800?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2018-10-23. Estimated completion is 2020-01-16.
What interventions are being tested in trial NCT03634800?
The interventions under investigation include: Radiation therapy (RADIATION), Nivolumab 240mg (DRUG).
Who is sponsoring clinical trial NCT03634800?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.